The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11395830 B1

Date of Patent:

Jul. 26, 2022

Filed:

Sep. 24, 2020

Methods for treating pulmonary non-tuberculous mycobacterial infections

Applicant:

Insmed Incorporated, Bridgewater, NJ (US);

Inventors:

Gina Eagle, Morristown, NJ (US);

Renu Gupta, Moorestown, NJ (US);

Assignee:

INSMED INCORPORATED, Bridgewater, NJ (US);

Attorney:

Cooley LLP

Primary Examiner:

Nannette Holloman

Int. Cl.

CPC ...

A61K 31/7036 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 9/127 (2006.01); A61P 31/04 (2006.01); A61K 31/133 (2006.01); A61K 31/407 (2006.01); A61K 31/4375 (2006.01); A61K 31/4409 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/5383 (2006.01); A61K 31/546 (2006.01); A61K 31/65 (2006.01); A61K 31/7048 (2006.01); A61K 31/7052 (2006.01);

U.S. Cl.

CPC ...

A61K 31/7036 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0078 (2013.01); A61K 9/127 (2013.01); A61K 31/133 (2013.01); A61K 31/407 (2013.01); A61K 31/4375 (2013.01); A61K 31/4409 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/5383 (2013.01); A61K 31/546 (2013.01); A61K 31/65 (2013.01); A61K 31/7048 (2013.01); A61K 31/7052 (2013.01); A61K 45/06 (2013.01); A61P 31/04 (2018.01);

Abstract

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

Find Patent Forward Citations